Lantheus appoints Julie Eastland as new board member Page 1

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical company dedicated to enabling clinicians to find, fight and track disease to improve patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and finance executive, to the Lantheus Board of Directors (“Board”), effective September 3, 2024. As an independent director, Ms. Eastland will serve on the Board's Audit Committee. Following Ms. Eastland's appointment, the Board will consist of ten directors, eight of whom will be independent.

“We are very pleased to welcome Julie Eastland to the Lantheus Board of Directors. Ms. Eastland's extensive biotechnology expertise in finance, strategic planning, operations and transactions will be invaluable as we continue to grow and innovate,” said Mary Anne Heino, Chairman of Lantheus. “Ms. Eastland's proven track record of driving financial success and strategic initiatives aligns with our vision for the future, and I am confident that Ms. Eastland's insights and leadership will play a critical role in leading our radiopharmaceutical company.”